telmisartan has been researched along with Cell Transformation, Neoplastic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aso, K; Haneda, M; Kanamori, H; Makino, Y; Nakade, Y; Nakao, H; Ohashi, T; Okada, M; Sato, K; Tamaki, Y; Yamauchi, T; Yokohama, S; Yoneda, M | 1 |
1 other study(ies) available for telmisartan and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Benzimidazoles; Benzoates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline Deficiency; Diet; Drug Evaluation, Preclinical; Fatty Liver; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Cirrhosis; Liver Neoplasms, Experimental; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Telmisartan; Vascular Endothelial Growth Factor A | 2013 |